Last reviewed · How we verify
Methotrexate Biodim® — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Methotrexate Biodim® (Methotrexate Biodim®) — Crossject.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methotrexate Biodim® TARGET | Methotrexate Biodim® | Crossject | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methotrexate Biodim® CI watch — RSS
- Methotrexate Biodim® CI watch — Atom
- Methotrexate Biodim® CI watch — JSON
- Methotrexate Biodim® alone — RSS
Cite this brief
Drug Landscape (2026). Methotrexate Biodim® — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-biodim. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab